登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，3月27日，Convalescent Plasma to Treat COVID-19 Possibilities and Challenges》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-28

  • Convalescent Plasma to Treat COVID-19

    Possibilities and Challenges

    John D. Roback, MD, PhD1; Jeannette Guarner, MD2

    Author Affiliations Article Information

    JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.4940

    In this issue of JAMA, Shen et al report findings from a preliminary study of 5 severely ill patients with coronavirus disease 2019 (COVID-19) who were treated in the Shenzhen Third People's Hospital, China, using plasma from recovered individuals.1 All patients had severe respiratory failure and were receiving mechanical ventilation; 1 needed extracorporeal membrane oxygenation (ECMO) and 2 had bacterial and/or fungal pneumonia. Four patients without coexisting diseases received convalescent plasma around hospital day 20, and a patient with hypertension and mitral valve insufficiency received the plasma transfusion at day 10. The donor plasma had demonstrable IgG and IgM anti–SARS-CoV-19 antibodies and neutralized the virus in in vitro cultures.

  • 原文来源：https://jamanetwork.com/journals/jama/fullarticle/2763982?resultClick=1
143浏览量
原文链接
相关报告

  • 《JAMA，6月3日，Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-05
    • Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial Ling Li, MD, PhD1,2; Wei Zhang, MD3,4; Yu Hu, MD, PhD5; et alXunliang Tong, MD, PhD6; Shangen Zheng, MD7; Juntao Yang, PhD8; Yujie Kong, MD1,2; Lili Ren, PhD9,10; Qing Wei, MD11; Heng Mei, MD, PhD5; Caiying Hu, MD12; Cuihua Tao, MD13,14; Ru Yang, MD15; Jue Wang, MD1,2; Yongpei Yu, PhD16; Yong Guo, PhD17; Xiaoxiong Wu, MD18; Zhihua Xu, MD12,19; Li Zeng, MD3,20; Nian Xiong, MD12,21; Lifeng Chen, MD22; Juan Wang, MD11; Ning Man, MD23; Yu Liu, PhD1; Haixia Xu, MD1,2; E. Deng, MS1; Xuejun Zhang, MS1; Chenyue Li, MD1,2; Conghui Wang, PhD9; Shisheng Su, PhD17; Linqi Zhang, PhD24; Jianwei Wang, PhD9,10; Yanyun Wu, MD, PhD25; Zhong Liu, MD, PhD1,2 Author Affiliations JAMA. Published online June 3, 2020. doi:10.1001/jama.2020.10044 Abstract Importance  Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. Objective  To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19. Design, Setting, and Participants  Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled.
    109浏览量
    原文链接

  • 《LANCET，2月27日，Convalescent plasma as a potential therapy for COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • Convalescent plasma as a potential therapy for COVID-19 Long Chen, Jing Xiong, Lei Bao, Yuan Shi Published:February 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30141-9 The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). By Feb 22, 2020, this virus has affected more than 77?700 people worldwide and caused more than 2300 deaths. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged.1 However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.
    115浏览量
    原文链接